首页 > 最新文献

JTCVS open最新文献

英文 中文
Impact of frailty on outcomes and readmissions after transcatheter and surgical aortic valve replacement in a national cohort 全国队列中体弱对经导管主动脉瓣置换术和手术主动脉瓣置换术后疗效和再住院率的影响
Pub Date : 2024-08-01 DOI: 10.1016/j.xjon.2024.05.006

Objective

We examined the effect of frailty on in-hospital mortality, readmission rates, and hospitalization costs after transcatheter and surgical aortic valve replacement in a population-level cohort.

Methods

The Nationwide Readmissions Database was queried for patients who underwent transcatheter or surgical aortic valve replacement during 2016-2018. Multivariate logistic regression was used to discern independent effects of frailty on outcomes. Kaplan–Meier time-to-event analysis was used to evaluate the effect of frailty on freedom from readmission.

Results

A total of 243,619 patients underwent aortic valve replacement: 142,786 (58.6%) transcatheter aortic valve replacements and 100,833 (41.4%) surgical aortic valve replacements. Frail patients constituted 16,388 (11.5%) and 7251 (7.2%) in the transcatheter aortic valve replacement and surgical aortic valve replacement cohorts, respectively. Compared with nonfrail patients, frail patients had greater in-hospital mortality (transcatheter aortic valve replacement: 3.2% vs 1.1%; surgical aortic valve replacement: 6.1% vs 2.0%; both P < .001), longer length of stay (transcatheter aortic valve replacement: 4 vs 2 days; surgical aortic valve replacement: 13 vs 6 days; P < .001), and greater cost (transcatheter aortic valve replacement: $51,654 vs $44,401; surgical aortic valve replacement: $60,782 vs $40,544; P < .001). Time-to-event analysis showed that frail patients had higher rates of readmission over the calendar year in both transcatheter aortic valve replacement (P < .001) and surgical aortic valve replacement (P < .001) cohorts. This association persisted on adjusted multivariate regression for mortality (transcatheter aortic valve replacement odds ratio [95% CI] 1.98 [1.65-2.37], surgical aortic valve replacement 1.96 [1.60-2.41]), 30-day readmission (transcatheter aortic valve replacement 1.38 [1.27-1.49], surgical aortic valve replacement 1.47 [1.30-1.65]), and 90-day readmission (transcatheter aortic valve replacement 1.41 [1.31-1.52], surgical aortic valve replacement 1.60 [1.43-1.79]) (P < .001 for all).

Conclusions

For patients undergoing transcatheter or surgical aortic valve replacement, frailty is associated with in-hospital mortality, readmission, and higher costs. Further efforts to optimize outcomes for frail patients are warranted.

目的我们在一个人群水平的队列中研究了虚弱对经导管主动脉瓣置换术和外科主动脉瓣置换术后的院内死亡率、再入院率和住院费用的影响。方法在全国再入院数据库中查询了2016-2018年间接受经导管主动脉瓣置换术或外科主动脉瓣置换术的患者。采用多变量逻辑回归分析虚弱对预后的独立影响。结果共有243619名患者接受了主动脉瓣置换术:其中142786人(58.6%)接受了经导管主动脉瓣置换术,100833人(41.4%)接受了外科主动脉瓣置换术。在经导管主动脉瓣置换术和外科主动脉瓣置换术组别中,体弱患者分别占16388人(11.5%)和7251人(7.2%)。与非体弱患者相比,体弱患者的院内死亡率更高(经导管主动脉瓣置换术:3.2% 对 1.1%):经导管主动脉瓣置换术:3.2% 对 1.1%;外科主动脉瓣置换术:6.1% 对 2.0%):6.1%对2.0%;P均为0.001),住院时间更长(经导管主动脉瓣置换术:4天对2天;外科主动脉瓣置换术:1天对1天;P均为0.001):4天 vs 2天;手术主动脉瓣置换术:13天 vs 6天;P经导管主动脉瓣置换术:51,654 美元 vs 44,401 美元;外科主动脉瓣置换术:60,782 美元 vs 40,544 美元;P <.001),费用更高(经导管主动脉瓣置换术:51,654 美元 vs 44,401 美元;外科主动脉瓣置换术:60,782 美元 vs 40,544 美元;P <.001)。时间到事件分析表明,在经导管主动脉瓣置换术(P <.001)和外科主动脉瓣置换术(P <.001)组别中,体弱患者在历年内的再入院率较高。这种关联在死亡率(经导管主动脉瓣置换术赔率 [95% CI] 1.98 [1.65-2.37],手术主动脉瓣置换术 1.96 [1.60-2.41])、30 天再入院(经导管主动脉瓣置换术 1.38 [1.27-1.49],手术主动脉瓣置换术 1.47 [1.30-1.65])、90 天再入院(经导管主动脉瓣置换术 1.38 [1.27-1.49],手术主动脉瓣置换术 1.47 [1.30-1.65])调整后的多变量回归中持续存在。结论对于接受经导管主动脉瓣置换术或外科主动脉瓣置换术的患者,虚弱与院内死亡率、再入院率和较高的费用相关。有必要进一步努力优化体弱患者的预后。
{"title":"Impact of frailty on outcomes and readmissions after transcatheter and surgical aortic valve replacement in a national cohort","authors":"","doi":"10.1016/j.xjon.2024.05.006","DOIUrl":"10.1016/j.xjon.2024.05.006","url":null,"abstract":"<div><h3>Objective</h3><p>We examined the effect of frailty on in-hospital mortality, readmission rates, and hospitalization costs after transcatheter and surgical aortic valve replacement in a population-level cohort.</p></div><div><h3>Methods</h3><p>The Nationwide Readmissions Database was queried for patients who underwent transcatheter or surgical aortic valve replacement during 2016-2018. Multivariate logistic regression was used to discern independent effects of frailty on outcomes. Kaplan–Meier time-to-event analysis was used to evaluate the effect of frailty on freedom from readmission.</p></div><div><h3>Results</h3><p>A total of 243,619 patients underwent aortic valve replacement: 142,786 (58.6%) transcatheter aortic valve replacements and 100,833 (41.4%) surgical aortic valve replacements. Frail patients constituted 16,388 (11.5%) and 7251 (7.2%) in the transcatheter aortic valve replacement and surgical aortic valve replacement cohorts, respectively. Compared with nonfrail patients, frail patients had greater in-hospital mortality (transcatheter aortic valve replacement: 3.2% vs 1.1%; surgical aortic valve replacement: 6.1% vs 2.0%; both <em>P &lt; .</em>001), longer length of stay (transcatheter aortic valve replacement: 4 vs 2 days; surgical aortic valve replacement: 13 vs 6 days; <em>P &lt; .</em>001), and greater cost (transcatheter aortic valve replacement: $51,654 vs $44,401; surgical aortic valve replacement: $60,782 vs $40,544; <em>P &lt; .</em>001). Time-to-event analysis showed that frail patients had higher rates of readmission over the calendar year in both transcatheter aortic valve replacement (<em>P &lt; .</em>001) and surgical aortic valve replacement (<em>P &lt; .</em>001) cohorts. This association persisted on adjusted multivariate regression for mortality (transcatheter aortic valve replacement odds ratio [95% CI] 1.98 [1.65-2.37], surgical aortic valve replacement 1.96 [1.60-2.41]), 30-day readmission (transcatheter aortic valve replacement 1.38 [1.27-1.49], surgical aortic valve replacement 1.47 [1.30-1.65]), and 90-day readmission (transcatheter aortic valve replacement 1.41 [1.31-1.52], surgical aortic valve replacement 1.60 [1.43-1.79]) (<em>P &lt; .</em>001 for all).</p></div><div><h3>Conclusions</h3><p>For patients undergoing transcatheter or surgical aortic valve replacement, frailty is associated with in-hospital mortality, readmission, and higher costs. Further efforts to optimize outcomes for frail patients are warranted.</p></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666273624001268/pdfft?md5=2078c170c38d3da488b94ad37327c314&pid=1-s2.0-S2666273624001268-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141141945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute brain injury risk prediction models in venoarterial extracorporeal membrane oxygenation patients with tree-based machine learning: An Extracorporeal Life Support Organization Registry analysis 基于树型机器学习的静脉体外膜氧合患者急性脑损伤风险预测模型:ELSO 登记分析
Pub Date : 2024-08-01 DOI: 10.1016/j.xjon.2024.06.001

Objective

We aimed to determine if machine learning can predict acute brain injury and to identify modifiable risk factors for acute brain injury in patients receiving venoarterial extracorporeal membrane oxygenation.

Methods

We included adults (age ≥18 years) receiving venoarterial extracorporeal membrane oxygenation or extracorporeal cardiopulmonary resuscitation in the Extracorporeal Life Support Organization Registry (2009-2021). Our primary outcome was acute brain injury: central nervous system ischemia, intracranial hemorrhage, brain death, and seizures. We used Random Forest, CatBoost, LightGBM, and XGBoost machine learning algorithms (10-fold leave-1-out cross-validation) to predict and identify features most important for acute brain injury. We extracted 65 total features: demographics, pre-extracorporeal membrane oxygenation/on-extracorporeal membrane oxygenation laboratory values, and pre-extracorporeal membrane oxygenation/on-extracorporeal membrane oxygenation settings.

Results

Of 35,855 patients receiving venoarterial extracorporeal membrane oxygenation (nonextracorporeal cardiopulmonary resuscitation) (median age of 57.8 years, 66% were male), 7.7% (n = 2769) experienced acute brain injury. In venoarterial extracorporeal membrane oxygenation (nonextracorporeal cardiopulmonary resuscitation), the area under the receiver operator characteristic curves to predict acute brain injury, central nervous system ischemia, and intracranial hemorrhage were 0.67, 0.67, and 0.62, respectively. The true-positive, true-negative, false-positive, false-negative, positive, and negative predictive values were 33%, 88%, 12%, 67%, 18%, and 94%, respectively, for acute brain injury. Longer extracorporeal membrane oxygenation duration, higher 24-hour extracorporeal membrane oxygenation pump flow, and higher on-extracorporeal membrane oxygenation partial pressure of oxygen were associated with acute brain injury. Of 10,775 patients receiving extracorporeal cardiopulmonary resuscitation (median age of 57.1 years, 68% were male), 16.5% (n = 1787) experienced acute brain injury. The area under the receiver operator characteristic curves for acute brain injury, central nervous system ischemia, and intracranial hemorrhage were 0.72, 0.73, and 0.69, respectively. Longer extracorporeal membrane oxygenation duration, older age, and higher 24-hour extracorporeal membrane oxygenation pump flow were associated with acute brain injury.

Conclusions

In the largest study predicting neurological complications with machine learning in extracorporeal membrane oxygenation, longer extracorporeal membrane oxygenation duration and higher 24-hour pump flow were associated with acute brain injury in nonextracorporeal cardiopulmonary resuscitation and extracorporeal cardiopulmonary resuscitation venoarterial extracorporeal membrane oxygenation.

方法 我们纳入了体外生命支持组织注册表(2009-2021 年)中接受静脉体外膜氧合或体外心肺复苏的成人(年龄≥18 岁)。我们的主要结果是急性脑损伤:中枢神经系统缺血、颅内出血、脑死亡和癫痫发作。我们使用随机森林(Random Forest)、CatBoost、LightGBM 和 XGBoost 机器学习算法(10-fold leave-1-out 交叉验证)来预测和识别对急性脑损伤最重要的特征。我们共提取了 65 个特征:人口统计学、体外膜氧合前/体外膜氧合时实验室值、体外膜氧合前/体外膜氧合时设置。结果 在 35855 名接受静脉体外膜氧合(非体外心肺复苏)的患者中(中位年龄为 57.8 岁,66% 为男性),7.7%(n = 2769)经历了急性脑损伤。在静脉体外膜肺氧合(非体外心肺复苏)中,预测急性脑损伤、中枢神经系统缺血和颅内出血的接收器操作者特征曲线下面积分别为 0.67、0.67 和 0.62。对急性脑损伤的真阳性、真阴性、假阳性、假阴性、阳性和阴性预测值分别为 33%、88%、12%、67%、18% 和 94%。较长的体外膜氧合持续时间、较高的 24 小时体外膜氧合泵流量和较高的体外膜氧合氧分压与急性脑损伤有关。在接受体外心肺复苏的10775名患者中(中位年龄为57.1岁,68%为男性),16.5%(n = 1787)的患者出现了急性脑损伤。急性脑损伤、中枢神经系统缺血和颅内出血的接受者操作特征曲线下面积分别为 0.72、0.73 和 0.69。结论 在利用机器学习预测体外膜肺氧合神经系统并发症的最大规模研究中,在非体外心肺复苏和体外心肺复苏静脉动脉体外膜肺氧合中,较长的体外膜肺氧合持续时间和较高的 24 小时泵流量与急性脑损伤有关。
{"title":"Acute brain injury risk prediction models in venoarterial extracorporeal membrane oxygenation patients with tree-based machine learning: An Extracorporeal Life Support Organization Registry analysis","authors":"","doi":"10.1016/j.xjon.2024.06.001","DOIUrl":"10.1016/j.xjon.2024.06.001","url":null,"abstract":"<div><h3>Objective</h3><p>We aimed to determine if machine learning can predict acute brain injury and to identify modifiable risk factors for acute brain injury in patients receiving venoarterial extracorporeal membrane oxygenation.</p></div><div><h3>Methods</h3><p>We included adults (age ≥18 years) receiving venoarterial extracorporeal membrane oxygenation or extracorporeal cardiopulmonary resuscitation in the Extracorporeal Life Support Organization Registry (2009-2021). Our primary outcome was acute brain injury: central nervous system ischemia, intracranial hemorrhage, brain death, and seizures. We used Random Forest, CatBoost, LightGBM, and XGBoost machine learning algorithms (10-fold leave-1-out cross-validation) to predict and identify features most important for acute brain injury. We extracted 65 total features: demographics, pre-extracorporeal membrane oxygenation/on-extracorporeal membrane oxygenation laboratory values, and pre-extracorporeal membrane oxygenation/on-extracorporeal membrane oxygenation settings.</p></div><div><h3>Results</h3><p>Of 35,855 patients receiving venoarterial extracorporeal membrane oxygenation (nonextracorporeal cardiopulmonary resuscitation) (median age of 57.8 years, 66% were male), 7.7% (n = 2769) experienced acute brain injury. In venoarterial extracorporeal membrane oxygenation (nonextracorporeal cardiopulmonary resuscitation), the area under the receiver operator characteristic curves to predict acute brain injury, central nervous system ischemia, and intracranial hemorrhage were 0.67, 0.67, and 0.62, respectively. The true-positive, true-negative, false-positive, false-negative, positive, and negative predictive values were 33%, 88%, 12%, 67%, 18%, and 94%, respectively, for acute brain injury. Longer extracorporeal membrane oxygenation duration, higher 24-hour extracorporeal membrane oxygenation pump flow, and higher on-extracorporeal membrane oxygenation partial pressure of oxygen were associated with acute brain injury. Of 10,775 patients receiving extracorporeal cardiopulmonary resuscitation (median age of 57.1 years, 68% were male), 16.5% (n = 1787) experienced acute brain injury. The area under the receiver operator characteristic curves for acute brain injury, central nervous system ischemia, and intracranial hemorrhage were 0.72, 0.73, and 0.69, respectively. Longer extracorporeal membrane oxygenation duration, older age, and higher 24-hour extracorporeal membrane oxygenation pump flow were associated with acute brain injury.</p></div><div><h3>Conclusions</h3><p>In the largest study predicting neurological complications with machine learning in extracorporeal membrane oxygenation, longer extracorporeal membrane oxygenation duration and higher 24-hour pump flow were associated with acute brain injury in nonextracorporeal cardiopulmonary resuscitation and extracorporeal cardiopulmonary resuscitation venoarterial extracorporeal membrane oxygenation.</p></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266627362400158X/pdfft?md5=f1b9a4ecc37da6d7d38af358fb63fcd7&pid=1-s2.0-S266627362400158X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141404140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunohistochemistry of p53 surrogates TP53 mutation as an accurate predictor for early-relapse of surgically resected stage I-III lung adenocarcinoma p53 代理基因 TP53 突变的免疫组化是手术切除的 I-III 期肺癌早期复发的准确预测指标
Pub Date : 2024-08-01 DOI: 10.1016/j.xjon.2024.06.005

Introduction

TP53 is a strong tumor suppressor gene; its deactivation contributes to carcinogenesis and influences clinical outcomes. However, the prognostic influence of p53 deactivation on early relapse in patients with surgically resected non–small cell lung cancer remains unclear.

Materials and methods

A cohort of 170 patients with primary stage I through III lung adenocarcinoma (LADC) and lung squamous cell carcinoma who underwent complete resection at Tokyo Medical and Dental University was screened for TP53 mutations using panel testing, and association studies between TP53 mutations and clinical data, including histology and postoperative recurrence, were performed. The association between TP53 mutations and postoperative recurrence was validated using data from 604 patients with MSK-IMPACT from The Cancer Genome Atlas. Additional immunohistochemistry for p53 was performed on some subsets of the Tokyo Medical and Dental University population.

Results

Mutations in TP53 were recurrently observed (35.9%; 61 out of 170) in the Tokyo Medical and Dental University cohort. In the histology-stratified analysis, patients with LADC histology showed TP53 mutations that were associated with poor relapse-free survival (log-rank test; P = .020), whereas patients with lung squamous cell carcinoma histology showed TP53 mutations that were not (P = .99). The poor prognosis of TP53 mutation-positive LADCs was validated in The Cancer Genome Atlas-LADC cohort (log-rank test; P = .0065). Additional immunohistochemistry for p53 in patients with LADC histology in the Tokyo Medical and Dental University cohort showed a significant correlation between TP53 mutations and abnormal IHC pattern of p53 (Cramer's correlation coefficient V = 0.67).

Conclusions

TP53 mutation is a potential marker for worse prognosis in surgically resected LADC; immunohistochemistry for p53 could be a surrogate method to identify patients with LADC with a worse prognosis.

导言TP53是一种强抑癌基因;其失活会导致癌变并影响临床预后。材料和方法在东京医科齿科大学接受完全切除术的 170 例原发性 I 至 III 期肺腺癌(LADC)和肺鳞癌患者队列中,使用面板测试筛查 TP53 突变,并进行 TP53 突变与临床数据(包括组织学和术后复发)之间的关联研究。利用癌症基因组图谱(The Cancer Genome Atlas)中604名MSK-IMPACT患者的数据验证了TP53突变与术后复发之间的关联。结果在东京医科齿科大学队列中反复观察到 TP53 突变(35.9%;170 例中有 61 例)。在组织学分层分析中,肺腺癌组织学患者的TP53突变与无复发生存率低有关(对数秩检验;P = .020),而肺鳞癌组织学患者的TP53突变与无复发生存率低无关(P = .99)。在癌症基因组图谱-LADC队列中验证了TP53突变阳性LADC的不良预后(对数rank检验;P = .0065)。结论TP53突变是手术切除的LADC预后较差的潜在标志物;p53免疫组化可作为一种替代方法来鉴别预后较差的LADC患者。
{"title":"Immunohistochemistry of p53 surrogates TP53 mutation as an accurate predictor for early-relapse of surgically resected stage I-III lung adenocarcinoma","authors":"","doi":"10.1016/j.xjon.2024.06.005","DOIUrl":"10.1016/j.xjon.2024.06.005","url":null,"abstract":"<div><h3>Introduction</h3><p><em>TP53</em> is a strong tumor suppressor gene; its deactivation contributes to carcinogenesis and influences clinical outcomes. However, the prognostic influence of p53 deactivation on early relapse in patients with surgically resected non–small cell lung cancer remains unclear.</p></div><div><h3>Materials and methods</h3><p>A cohort of 170 patients with primary stage I through III lung adenocarcinoma (LADC) and lung squamous cell carcinoma who underwent complete resection at Tokyo Medical and Dental University was screened for <em>TP53</em> mutations using panel testing, and association studies between <em>TP53</em> mutations and clinical data, including histology and postoperative recurrence, were performed. The association between <em>TP53</em> mutations and postoperative recurrence was validated using data from 604 patients with MSK-IMPACT from The Cancer Genome Atlas. Additional immunohistochemistry for p53 was performed on some subsets of the Tokyo Medical and Dental University population.</p></div><div><h3>Results</h3><p>Mutations in <em>TP53</em> were recurrently observed (35.9%; 61 out of 170) in the Tokyo Medical and Dental University cohort. In the histology-stratified analysis, patients with LADC histology showed <em>TP53</em> mutations that were associated with poor relapse-free survival (log-rank test; <em>P</em> = .020), whereas patients with lung squamous cell carcinoma histology showed <em>TP53</em> mutations that were not (<em>P</em> = .99). The poor prognosis of <em>TP53</em> mutation-positive LADCs was validated in The Cancer Genome Atlas-LADC cohort (log-rank test; <em>P</em> = .0065). Additional immunohistochemistry for p53 in patients with LADC histology in the Tokyo Medical and Dental University cohort showed a significant correlation between <em>TP53</em> mutations and abnormal IHC pattern of p53 (Cramer's correlation coefficient <em>V</em> = 0.67).</p></div><div><h3>Conclusions</h3><p><em>TP53</em> mutation is a potential marker for worse prognosis in surgically resected LADC; immunohistochemistry for p53 could be a surrogate method to identify patients with LADC with a worse prognosis.</p></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666273624001633/pdfft?md5=b2e273399d2e8d3368926b8e17bfc5c7&pid=1-s2.0-S2666273624001633-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141399748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pathway to cardiothoracic surgery: A primer for aspiring students 通往心胸外科之路:有抱负的学生入门指南
Pub Date : 2024-08-01 DOI: 10.1016/j.xjon.2024.05.013

Objective

The pathway to cardiothoracic surgery is often obscure for premedical students and aspiring applicants and requires navigating various known and unknown obstacles. Recognizing the challenges encountered on the path to a career in cardiothoracic surgery in the United States, we present this guide for students interested in the field to maximize success in their premedical, preclinical, and preresidency years.

Methods

This is a joint collaboration between the Thoracic Surgery Residents Association and the Thoracic Surgery Medical Student Association. Drawing from firsthand experiences and insights gathered from numerous student applicants and current surgical residents, a comprehensive guide was constructed for students from the point of undergraduate school to advanced training options, including super-fellowship training.

Results

Several intricacies to cardiothoracic surgery career planning were discussed, including differences between traditional and integrated/fast-track pathways, college and medical school selection, networking, performing during clinical rotations, extracurricular and research activities, building mentorship relationships, and pursuing alternate career and advanced training opportunities.

Conclusions

For premedical students and aspiring applicants, the road to cardiothoracic surgery requires meticulous planning, grit, and thoughtful dedication. This document consolidates firsthand insights and advice from numerous aspiring and matched applicants to serve as a comprehensive guide for students seeking a career in cardiovascular and thoracic surgery.

目的通往心胸外科的道路对于医学预科生和有抱负的申请者来说往往是晦涩难懂的,需要克服各种已知和未知的障碍。认识到在美国心胸外科职业道路上遇到的挑战,我们为对该领域感兴趣的学生提供了这一指南,以最大限度地帮助他们在医学预科、临床前和实习前取得成功。根据从众多申请学生和现任外科住院医师那里收集到的第一手经验和见解,为学生们编写了一份从本科到高级培训选择(包括超级奖学金培训)的综合指南。结果讨论了心胸外科职业规划的一些复杂问题,包括传统途径和综合/快速通道之间的差异、大学和医学院的选择、人际关系网络、临床轮转期间的表现、课外和研究活动、建立导师关系以及寻求其他职业和高级培训机会。本文综合了众多有抱负和符合条件的申请者的第一手见解和建议,为寻求心血管和胸外科职业的学生提供了一份全面的指南。
{"title":"Pathway to cardiothoracic surgery: A primer for aspiring students","authors":"","doi":"10.1016/j.xjon.2024.05.013","DOIUrl":"10.1016/j.xjon.2024.05.013","url":null,"abstract":"<div><h3>Objective</h3><p>The pathway to cardiothoracic surgery is often obscure for premedical students and aspiring applicants and requires navigating various known and unknown obstacles. Recognizing the challenges encountered on the path to a career in cardiothoracic surgery in the United States, we present this guide for students interested in the field to maximize success in their premedical, preclinical, and preresidency years.</p></div><div><h3>Methods</h3><p>This is a joint collaboration between the Thoracic Surgery Residents Association and the Thoracic Surgery Medical Student Association. Drawing from firsthand experiences and insights gathered from numerous student applicants and current surgical residents, a comprehensive guide was constructed for students from the point of undergraduate school to advanced training options, including super-fellowship training.</p></div><div><h3>Results</h3><p>Several intricacies to cardiothoracic surgery career planning were discussed, including differences between traditional and integrated/fast-track pathways, college and medical school selection, networking, performing during clinical rotations, extracurricular and research activities, building mentorship relationships, and pursuing alternate career and advanced training opportunities.</p></div><div><h3>Conclusions</h3><p>For premedical students and aspiring applicants, the road to cardiothoracic surgery requires meticulous planning, grit, and thoughtful dedication. This document consolidates firsthand insights and advice from numerous aspiring and matched applicants to serve as a comprehensive guide for students seeking a career in cardiovascular and thoracic surgery.</p></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666273624001347/pdfft?md5=2f476743f4b286e201aa1f675e4e7733&pid=1-s2.0-S2666273624001347-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141279297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standardized intrapulmonary lymph node dissection in lung cancer specimens: A national Colombian analysis 肺癌标本的标准化肺内淋巴结清扫:哥伦比亚全国分析
Pub Date : 2024-08-01 DOI: 10.1016/j.xjon.2024.06.004

Objective

In patients with non–small cell lung cancer, lymph node assessment is essential for appropriate staging. The intrapulmonary lymph nodes (IPLNs) should be considered when assigning the N stage but are infrequently evaluated in Colombian centers, resulting in understaging that may hinder optimal treatment.

Methods

We conducted a prospective study of IPLN dissection in patients with clinical stage I or II non–small cell lung cancer who underwent surgical resection at 9 institutions in Colombia between 2021 and 2023. IPLN dissection was performed by trained surgeons who collected lymph nodes from fresh specimens after resection and before formalin fixation.

Results

One hundred patients were eligible for the analysis. Their mean age was 67 ± 10.9 years, and 76% were women. Most (74%) had adenocarcinoma, 20% had neuroendocrine tumors, and 6% had squamous cell carcinoma. Successful sampling and histopathologic analysis of at least one IPLN station was obtained in 85% of patients, 9% had upstaging due to positive N2 lymph nodes, and 5% had upstaging due to positive N1 lymph nodes. Among the patients with pN0 or pN1 disease, 3.2% (3 out of 91) were upstaged exclusively due to positive IPLNs.

Conclusions

Fresh-specimen dissection to collect IPLNs is appropriate and feasible to achieve more accurate pathological staging in Colombian lung cancer patients. In clinical N0 patients, IPLN dissection maximizes selection for adjuvant therapy.

目的 在非小细胞肺癌患者中,淋巴结评估是进行适当分期的关键。方法我们对 2021 年至 2023 年期间在哥伦比亚 9 家机构接受手术切除的临床 I 期或 II 期非小细胞肺癌患者的 IPLN 切除进行了前瞻性研究。IPLN切除术由训练有素的外科医生进行,他们在切除术后、福尔马林固定前从新鲜标本中收集淋巴结。他们的平均年龄为 67 ± 10.9 岁,76% 为女性。大多数(74%)为腺癌,20%为神经内分泌肿瘤,6%为鳞癌。85%的患者至少对一个IPLN站进行了成功取样和组织病理学分析,9%的患者因N2淋巴结阳性而上行分期,5%的患者因N1淋巴结阳性而上行分期。结论对哥伦比亚肺癌患者进行新鲜标本清扫以收集 IPLN 对实现更准确的病理分期是适当和可行的。在临床 N0 患者中,IPLN 剖检能最大限度地选择辅助治疗。
{"title":"Standardized intrapulmonary lymph node dissection in lung cancer specimens: A national Colombian analysis","authors":"","doi":"10.1016/j.xjon.2024.06.004","DOIUrl":"10.1016/j.xjon.2024.06.004","url":null,"abstract":"<div><h3>Objective</h3><p>In patients with non–small cell lung cancer, lymph node assessment is essential for appropriate staging. The intrapulmonary lymph nodes (IPLNs) should be considered when assigning the N stage but are infrequently evaluated in Colombian centers, resulting in understaging that may hinder optimal treatment.</p></div><div><h3>Methods</h3><p>We conducted a prospective study of IPLN dissection in patients with clinical stage I or II non–small cell lung cancer who underwent surgical resection at 9 institutions in Colombia between 2021 and 2023. IPLN dissection was performed by trained surgeons who collected lymph nodes from fresh specimens after resection and before formalin fixation.</p></div><div><h3>Results</h3><p>One hundred patients were eligible for the analysis. Their mean age was 67 ± 10.9 years, and 76% were women. Most (74%) had adenocarcinoma, 20% had neuroendocrine tumors, and 6% had squamous cell carcinoma. Successful sampling and histopathologic analysis of at least one IPLN station was obtained in 85% of patients, 9% had upstaging due to positive N2 lymph nodes, and 5% had upstaging due to positive N1 lymph nodes. Among the patients with pN0 or pN1 disease, 3.2% (3 out of 91) were upstaged exclusively due to positive IPLNs.</p></div><div><h3>Conclusions</h3><p>Fresh-specimen dissection to collect IPLNs is appropriate and feasible to achieve more accurate pathological staging in Colombian lung cancer patients. In clinical N0 patients, IPLN dissection maximizes selection for adjuvant therapy.</p></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666273624001621/pdfft?md5=ac7a6b66c781373ad6a6aa480eb7b6e0&pid=1-s2.0-S2666273624001621-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141961087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying Asian American lung cancer disparities: A novel analytic approach 识别亚裔美国人的肺癌差异:新颖的分析方法
Pub Date : 2024-08-01 DOI: 10.1016/j.xjon.2024.04.010

Objective

Asian Americans include heterogeneous subpopulations with unique burden as the only racial group with cancer as the leading cause of death. The purpose of the study was to identify differences in clinical stage and survival of patients with lung cancer between Asian Americans and its subgroups relative to other racial groups.

Methods

Patients with lung cancer from 2016 National Cancer Database were divided into East Asian, Southeast Asian, South Asian subgroups based on geographic origins, and a composite Asian American group with White non-Hispanic, Black, and Hispanic comparison groups. Columnar z score analysis with adjusted residuals was employed and the terms underrepresented and overrepresented were utilized to describe significant statistical findings.

Results

A total of 825,448 patients were analyzed. Asian Americans were underrepresented relative to White non-Hispanics in all clinical stages except IIIB and IV. In clinical stage IV, Asian Americans (51.0%), East Asians (47.2%), Southeast Asians (57.4%), and South Asians (52.2%) were overrepresented relative to White non-Hispanics (42.2%) and Southeast Asians were overrepresented relative to East Asians and South Asians. For survival across all stages, Asian Americans were overrepresented relative to White non-Hispanics and Blacks, but in clinical stage IV, Southeast Asians (17.9%) were underrepresented relative to East Asians (26.0%) and South Asians (26.6%).

Conclusions

This is the first study to address lung cancer disparity in Asian American subgroups employing a novel analytical approach. Asian American subgroups demonstrated more advanced lung cancer diagnosis yet higher survival compared with White non-Hispanics, Blacks, and/or Hispanics with differences between subgroups. Interplay of complex factors may contribute to Asian American health disparities.

目的美国亚裔包括异质性亚人群,作为唯一以癌症为主要死因的种族群体,他们承受着独特的负担。该研究旨在确定亚裔美国人及其亚群肺癌患者的临床分期和生存率相对于其他种族群体的差异。方法将 2016 年国家癌症数据库中的肺癌患者根据地理来源分为东亚、东南亚、南亚亚群,以及亚裔美国人综合组和非西班牙裔白人、黑人和西班牙裔对比组。采用调整残差的柱状 Z 值分析法,并使用代表性不足和代表性过高两个术语来描述重要的统计结果。与非西班牙裔白人相比,亚裔美国人在除IIIB和IV期以外的所有临床分期中的比例都偏低。在临床 IV 期,相对于非西班牙裔白人(42.2%),亚裔美国人(51.0%)、东亚人(47.2%)、东南亚人(57.4%)和南亚人(52.2%)的比例偏高,而相对于东亚人和南亚人,东南亚人的比例偏高。在所有分期的生存率方面,亚裔美国人相对于非西班牙裔白人和黑人的比例偏高,但在临床IV期,东南亚人(17.9%)相对于东亚人(26.0%)和南亚人(26.6%)的比例偏低。与非西班牙裔白人、黑人和/或西班牙裔美国人相比,亚裔美国人亚群的肺癌诊断较晚,但生存率较高,亚群之间存在差异。各种复杂因素的相互作用可能会导致亚裔美国人的健康差异。
{"title":"Identifying Asian American lung cancer disparities: A novel analytic approach","authors":"","doi":"10.1016/j.xjon.2024.04.010","DOIUrl":"10.1016/j.xjon.2024.04.010","url":null,"abstract":"<div><h3>Objective</h3><p>Asian Americans include heterogeneous subpopulations with unique burden as the only racial group with cancer as the leading cause of death. The purpose of the study was to identify differences in clinical stage and survival of patients with lung cancer between Asian Americans and its subgroups relative to other racial groups.</p></div><div><h3>Methods</h3><p>Patients with lung cancer from 2016 National Cancer Database were divided into East Asian, Southeast Asian, South Asian subgroups based on geographic origins, and a composite Asian American group with White non-Hispanic, Black, and Hispanic comparison groups. Columnar <em>z</em> score analysis with adjusted residuals was employed and the terms underrepresented and overrepresented were utilized to describe significant statistical findings.</p></div><div><h3>Results</h3><p>A total of 825,448 patients were analyzed. Asian Americans were underrepresented relative to White non-Hispanics in all clinical stages except IIIB and IV. In clinical stage IV, Asian Americans (51.0%), East Asians (47.2%), Southeast Asians (57.4%), and South Asians (52.2%) were overrepresented relative to White non-Hispanics (42.2%) and Southeast Asians were overrepresented relative to East Asians and South Asians. For survival across all stages, Asian Americans were overrepresented relative to White non-Hispanics and Blacks, but in clinical stage IV, Southeast Asians (17.9%) were underrepresented relative to East Asians (26.0%) and South Asians (26.6%).</p></div><div><h3>Conclusions</h3><p>This is the first study to address lung cancer disparity in Asian American subgroups employing a novel analytical approach. Asian American subgroups demonstrated more advanced lung cancer diagnosis yet higher survival compared with White non-Hispanics, Blacks, and/or Hispanics with differences between subgroups. Interplay of complex factors may contribute to Asian American health disparities.</p></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266627362400113X/pdfft?md5=327ca1fe48289ed580cc8782ccb92e52&pid=1-s2.0-S266627362400113X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140779911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors for thromboembolic events in pediatric patients with ventricular assist devices 使用心室辅助装置的儿科患者血栓栓塞事件的风险因素
Pub Date : 2024-08-01 DOI: 10.1016/j.xjon.2024.05.007

Objective

Pediatric patients on ventricular assist devices (VAD) are at risk of thromboembolic (TE) complications. Our objective was to identify factors associated with TE events, including the role of initial anticoagulation strategy and device type in the pediatric VAD population.

Methods

This was a retrospective, single-center review (2005-2022) of children who were implanted with paracorporeal pulsatile (PP), paracorporeal continuous (PC), or a combination of devices. Patient- and device-related factors were collected. Kaplan-Meier survival analysis was performed to determine freedom from TE. Cox proportional hazard analysis was conducted to look for factors associated with TE events.

Results

Ninety-five patients included with a median age of 0.9 years (interquartile range, 0.3, 5.4); median weight of 8.4 kg (interquartile range, 4.5, 17.8), and 63.2% with noncongenital heart disease. Device breakdown included 47.4% PC, 24.2% PP, and 23.2% combination of devices. Initial anticoagulation was either heparin (61.5%) or bivalirudin (38.5%). In Kaplan-Meier analysis, unadjusted freedom from a TE event was significantly greater in those who received bivalirudin as their initial anticoagulation strategy (P = .02) and PP VADs (P = .02). In multivariate analysis, initial anticoagulation strategy with bivalirudin (hazard ratio, 0.30; 95% confidence interval, 0.12-0.75, P = .01) was associated with a reduced hazard of TE events, whereas PC device strategy was found to be associated with an increased hazard (hazard ratio, 2.78; 95% confidence interval, 1.12-6.88, P = .03).

Conclusions

This study suggests that PC device strategy and heparin as an initial anticoagulation strategy are associated with increased hazard of TE events. Further research is required to understand the interaction between device type and initial anticoagulation strategy.

目的使用心室辅助装置(VAD)的儿童患者面临血栓栓塞(TE)并发症的风险。方法这是一项回顾性单中心研究(2005-2022 年),研究对象为植入体外脉冲式 (PP)、体外连续式 (PC) 或多种设备的儿童。收集了与患者和设备相关的因素。进行了卡普兰-梅耶生存分析,以确定是否脱离 TE。结果95名患者的中位年龄为0.9岁(四分位距为0.3-5.4岁),中位体重为8.4公斤(四分位距为4.5-17.8公斤),63.2%患有非先天性心脏病。设备分类包括 47.4% 的 PC、24.2% 的 PP 和 23.2% 的组合设备。初始抗凝药物为肝素(61.5%)或比伐卢定(38.5%)。在 Kaplan-Meier 分析中,接受比伐卢定作为初始抗凝策略(P = .02)和 PP VADs(P = .02)的患者未经调整的 TE 事件发生率明显更高。在多变量分析中,使用比伐卢定的初始抗凝策略(危险比为 0.30;95% 置信区间为 0.12-0.75,P = .01)与 TE 事件危险降低相关,而 PC 设备策略与危险增加相关(危险比为 2.78;95% 置信区间为 1.12-6.88,P = .03)。要了解设备类型和初始抗凝策略之间的相互作用,还需要进一步的研究。
{"title":"Risk factors for thromboembolic events in pediatric patients with ventricular assist devices","authors":"","doi":"10.1016/j.xjon.2024.05.007","DOIUrl":"10.1016/j.xjon.2024.05.007","url":null,"abstract":"<div><h3>Objective</h3><p>Pediatric patients on ventricular assist devices (VAD) are at risk of thromboembolic (TE) complications. Our objective was to identify factors associated with TE events, including the role of initial anticoagulation strategy and device type in the pediatric VAD population.</p></div><div><h3>Methods</h3><p>This was a retrospective, single-center review (2005-2022) of children who were implanted with paracorporeal pulsatile (PP), paracorporeal continuous (PC), or a combination of devices. Patient- and device-related factors were collected. Kaplan-Meier survival analysis was performed to determine freedom from TE. Cox proportional hazard analysis was conducted to look for factors associated with TE events.</p></div><div><h3>Results</h3><p>Ninety-five patients included with a median age of 0.9 years (interquartile range, 0.3, 5.4); median weight of 8.4 kg (interquartile range, 4.5, 17.8), and 63.2% with noncongenital heart disease. Device breakdown included 47.4% PC, 24.2% PP, and 23.2% combination of devices. Initial anticoagulation was either heparin (61.5%) or bivalirudin (38.5%). In Kaplan-Meier analysis, unadjusted freedom from a TE event was significantly greater in those who received bivalirudin as their initial anticoagulation strategy (<em>P</em> = .02) and PP VADs (<em>P</em> = .02). In multivariate analysis, initial anticoagulation strategy with bivalirudin (hazard ratio, 0.30; 95% confidence interval, 0.12-0.75, <em>P</em> = .01) was associated with a reduced hazard of TE events, whereas PC device strategy was found to be associated with an increased hazard (hazard ratio, 2.78; 95% confidence interval, 1.12-6.88, <em>P</em> = .03).</p></div><div><h3>Conclusions</h3><p>This study suggests that PC device strategy and heparin as an initial anticoagulation strategy are associated with increased hazard of TE events. Further research is required to understand the interaction between device type and initial anticoagulation strategy.</p></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266627362400127X/pdfft?md5=8605df4d9e9de4c9419e96624a383e0f&pid=1-s2.0-S266627362400127X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141131531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucose metabolism transcriptome clustering identifies subsets of resectable lung adenocarcinoma with different prognoses 葡萄糖代谢转录组聚类分析确定了不同预后的可切除肺腺癌亚群
Pub Date : 2024-08-01 DOI: 10.1016/j.xjon.2024.06.010

Objectives

Reprogramming of energy metabolism is a well-established hallmark of cancer, with aerobic glycolysis classically considered a prominent feature. We investigate the heterogeneity in glucose metabolism pathways within resectable primary lung adenocarcinoma and its clinical significance.

Methods

Using The Cancer Genome Atlas data, RNA expressions were extracted from 489 primary lung adenocarcinoma samples. Prognostic influence of glycolytic, aerobic, and mitochondrial markers (monocarboxylate transporter [MCT]4, MCT1, and translocase of outer mitochondrial membrane 20, respectively) was assessed using Kaplan-Meier analysis. Clustering of 35 genes involved in glucose metabolism was performed using the k-means method. The clusters were then analyzed for associations with demographic, clinical, and pathologic variables. Overall survival was assessed using the Kaplan-Meier estimator. Multivariate analysis was performed to assess the independent prognostic value of cluster membership.

Results

Classical statistical approach showed that higher expression of MCT4 was associated with a significantly worse prognosis. Increased expression of translocase of outer mitochondrial membrane 20 was associated with a nonsignificant trend toward better prognosis, and increased expression of MCT1 was associated with a better outcome. Clustering identified 3 major metabolic phenotypes, dominantly hypometabolic, dominantly oxidative, and dominantly mixed oxidative/glycolytic with significantly different pathologic stage distribution and prognosis; mixed oxidative/glycolytic was associated with worse survival. Cluster membership was independently associated with survival.

Conclusions

This study demonstrates the existence of distinct glucose metabolism clusters in resectable lung adenocarcinoma, providing valuable prognostic information. The findings highlight the potential relevance of considering metabolic profiles when designing strategies for reprogramming energy metabolism. Further studies are warranted to validate these findings in different cancer types and populations.

目的能量代谢的程序化是癌症的一个公认特征,有氧糖酵解通常被认为是癌症的一个突出特征。我们研究了可切除原发性肺腺癌中葡萄糖代谢通路的异质性及其临床意义。方法利用癌症基因组图谱数据,从 489 个原发性肺腺癌样本中提取 RNA 表达。采用 Kaplan-Meier 分析法评估了糖酵解、有氧和线粒体标记物(分别为单羧酸盐转运体 [MCT]4、MCT1 和线粒体外膜转运酶 20)对预后的影响。使用 k-means 方法对涉及葡萄糖代谢的 35 个基因进行了聚类。然后分析聚类与人口统计学、临床和病理学变量之间的关联。采用 Kaplan-Meier 估计法评估总生存率。结果经典统计方法显示,MCT4表达量越高,预后越差。线粒体外膜易位酶20表达量的增加与预后较好的趋势无显著相关性,而MCT1表达量的增加与预后较好的趋势相关。聚类确定了3种主要的代谢表型:显性低代谢型、显性氧化型和显性氧化/糖酵解混合型,其病理分期分布和预后有显著差异;氧化/糖酵解混合型与较差的生存率相关。结论这项研究表明,在可切除肺腺癌中存在不同的葡萄糖代谢簇,提供了有价值的预后信息。研究结果凸显了在设计能量代谢重编程策略时考虑代谢特征的潜在相关性。有必要开展进一步研究,在不同癌症类型和人群中验证这些发现。
{"title":"Glucose metabolism transcriptome clustering identifies subsets of resectable lung adenocarcinoma with different prognoses","authors":"","doi":"10.1016/j.xjon.2024.06.010","DOIUrl":"10.1016/j.xjon.2024.06.010","url":null,"abstract":"<div><h3>Objectives</h3><p>Reprogramming of energy metabolism is a well-established hallmark of cancer, with aerobic glycolysis classically considered a prominent feature. We investigate the heterogeneity in glucose metabolism pathways within resectable primary lung adenocarcinoma and its clinical significance.</p></div><div><h3>Methods</h3><p>Using The Cancer Genome Atlas data, RNA expressions were extracted from 489 primary lung adenocarcinoma samples. Prognostic influence of glycolytic, aerobic, and mitochondrial markers (monocarboxylate transporter [<em>MCT</em>]<em>4</em>, <em>MCT1</em>, and translocase of outer mitochondrial membrane 20, respectively) was assessed using Kaplan-Meier analysis. Clustering of 35 genes involved in glucose metabolism was performed using the k-means method. The clusters were then analyzed for associations with demographic, clinical, and pathologic variables. Overall survival was assessed using the Kaplan-Meier estimator. Multivariate analysis was performed to assess the independent prognostic value of cluster membership.</p></div><div><h3>Results</h3><p>Classical statistical approach showed that higher expression of <em>MCT4</em> was associated with a significantly worse prognosis. Increased expression of translocase of outer mitochondrial membrane 20 was associated with a nonsignificant trend toward better prognosis, and increased expression of <em>MCT1</em> was associated with a better outcome. Clustering identified 3 major metabolic phenotypes, dominantly hypometabolic, dominantly oxidative, and dominantly mixed oxidative/glycolytic with significantly different pathologic stage distribution and prognosis; mixed oxidative/glycolytic was associated with worse survival. Cluster membership was independently associated with survival.</p></div><div><h3>Conclusions</h3><p>This study demonstrates the existence of distinct glucose metabolism clusters in resectable lung adenocarcinoma, providing valuable prognostic information. The findings highlight the potential relevance of considering metabolic profiles when designing strategies for reprogramming energy metabolism. Further studies are warranted to validate these findings in different cancer types and populations.</p></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666273624001700/pdfft?md5=549d646bd7031928c81d824ba24e7ce6&pid=1-s2.0-S2666273624001700-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141961056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term outcomes of primary surgical repair for communicating DeBakey IIIb chronic dissecting aortic aneurysm 沟通型 DeBakey IIIb 慢性主动脉夹层动脉瘤初次手术修复的长期疗效
Pub Date : 2024-08-01 DOI: 10.1016/j.xjon.2024.05.009

Objective

This study aimed to evaluate the long-term outcomes of surgical strategies for communicating DeBakey IIIb chronic dissecting aortic aneurysm, considering the optimal primary surgical repair to prevent aortic events.

Methods

From 2002 to 2021, 101 patients with communicating DeBakey IIIb chronic dissecting aortic aneurysm who underwent surgical repair were categorized based on the primary surgical repair: 1-stage repair of thoracoabdominal aortic aneurysm (TAAAR) (n = 22) or staged repair, such as descending thoracic aneurysm repair (DTAR) (n = 43) or total arch replacement with elephant trunk implantation (TARET) (n = 25), and thoracic endovascular aortic repair (TEVAR) (n = 11). Early and late postoperative outcomes were compared among the groups.

Results

Early outcomes for TAAAR, DTAR, TARET, and TEVAR were associated with the incidence of stroke (9.1% vs 0% vs 4.0% vs 9.1%, respectively), spinal cord injury (13.6% vs 4.7% vs 8.0% vs 0%, respectively), and in-hospital mortality (9.1% vs 2.3% vs 0% vs 9.1%, respectively). During follow-up, the 10-year overall survival and 7-year aortic event-free rates for TAAAR, DTAR, TARET, and TEVAR were 61.8%, 71.6%, 21.5%, and 26.5% and 93.8%, 84.3%, 74.4%, and 51.4%, respectively. TAAAR had significantly higher overall survival (P = .05) and aortic event-free rates (P = .03) than TEVAR. TARET (hazard ratio, 2.27; P < .01) and TEVAR (hazard ratio, 3.40; P < .01) were independently associated with the incidence of aortic events during follow-up.

Conclusions

Considering the optimal primary surgical repair based on long-term outcomes, TEVAR was not a durable treatment option. Patient-specific TAAAR or DTAR should be considered rather than defaulting to minimally invasive primary repairs for all patients with communicating DeBakey IIIb chronic dissecting aortic aneurysm.

本研究旨在评估沟通型DeBakey IIIb慢性剥离性主动脉瘤手术策略的长期疗效,同时考虑到预防主动脉事件的最佳主要手术修复方法。方法从2002年到2021年,101例沟通型DeBakey IIIb慢性剥离性主动脉瘤患者接受了手术修复,根据主要手术修复方法进行分类:一期胸腹主动脉瘤修补术(TAAAR)(22 例)或分期修补术,如降胸动脉瘤修补术(DTAR)(43 例)或象鼻干植入全弓置换术(TARET)(25 例),以及胸腔内血管主动脉修补术(TEVAR)(11 例)。结果TAAAR、DTAR、TARET和TEVAR的早期结果与中风(分别为9.1% vs 0% vs 4.0% vs 9.1%)、脊髓损伤(分别为13.6% vs 4.7% vs 8.0% vs 0%)和院内死亡率(分别为9.1% vs 2.3% vs 0% vs 9.1%)相关。在随访期间,TAAAR、DTAR、TARET和TEVAR的10年总生存率和7年无主动脉事件发生率分别为61.8%、71.6%、21.5%和26.5%,以及93.8%、84.3%、74.4%和51.4%。TAAAR 的总生存率(P = .05)和无主动脉事件发生率(P = .03)明显高于 TEVAR。TARET(危险比,2.27;P <.01)和 TEVAR(危险比,3.40;P <.01)与随访期间主动脉事件的发生率独立相关。对于所有患有交流性DeBakey IIIb型慢性剥脱性主动脉瘤的患者,应考虑针对患者的TAAAR或DTAR,而不是默认采用微创初级修复术。
{"title":"Long-term outcomes of primary surgical repair for communicating DeBakey IIIb chronic dissecting aortic aneurysm","authors":"","doi":"10.1016/j.xjon.2024.05.009","DOIUrl":"10.1016/j.xjon.2024.05.009","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to evaluate the long-term outcomes of surgical strategies for communicating DeBakey IIIb chronic dissecting aortic aneurysm, considering the optimal primary surgical repair to prevent aortic events.</p></div><div><h3>Methods</h3><p>From 2002 to 2021, 101 patients with communicating DeBakey IIIb chronic dissecting aortic aneurysm who underwent surgical repair were categorized based on the primary surgical repair: 1-stage repair of thoracoabdominal aortic aneurysm (TAAAR) (n = 22) or staged repair, such as descending thoracic aneurysm repair (DTAR) (n = 43) or total arch replacement with elephant trunk implantation (TARET) (n = 25), and thoracic endovascular aortic repair (TEVAR) (n = 11). Early and late postoperative outcomes were compared among the groups.</p></div><div><h3>Results</h3><p>Early outcomes for TAAAR, DTAR, TARET, and TEVAR were associated with the incidence of stroke (9.1% vs 0% vs 4.0% vs 9.1%, respectively), spinal cord injury (13.6% vs 4.7% vs 8.0% vs 0%, respectively), and in-hospital mortality (9.1% vs 2.3% vs 0% vs 9.1%, respectively). During follow-up, the 10-year overall survival and 7-year aortic event-free rates for TAAAR, DTAR, TARET, and TEVAR were 61.8%, 71.6%, 21.5%, and 26.5% and 93.8%, 84.3%, 74.4%, and 51.4%, respectively. TAAAR had significantly higher overall survival (<em>P</em> = .05) and aortic event-free rates (<em>P</em> = .03) than TEVAR. TARET (hazard ratio, 2.27; <em>P</em> &lt; .01) and TEVAR (hazard ratio, 3.40; <em>P</em> &lt; .01) were independently associated with the incidence of aortic events during follow-up.</p></div><div><h3>Conclusions</h3><p>Considering the optimal primary surgical repair based on long-term outcomes, TEVAR was not a durable treatment option. Patient-specific TAAAR or DTAR should be considered rather than defaulting to minimally invasive primary repairs for all patients with communicating DeBakey IIIb chronic dissecting aortic aneurysm.</p></div>","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666273624001293/pdfft?md5=12a1cfd48f6c60ac1e3e2435c9c36f1e&pid=1-s2.0-S2666273624001293-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141960983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prophylaxis for postoperative atrial fibrillation: Impact of the implementation of a medication bundle protocol 术后心房颤动的预防:实施药物捆绑协议的影响
Pub Date : 2024-08-01 DOI: 10.1016/j.xjon.2024.05.014
{"title":"Prophylaxis for postoperative atrial fibrillation: Impact of the implementation of a medication bundle protocol","authors":"","doi":"10.1016/j.xjon.2024.05.014","DOIUrl":"10.1016/j.xjon.2024.05.014","url":null,"abstract":"","PeriodicalId":74032,"journal":{"name":"JTCVS open","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666273624001591/pdfft?md5=26cf9000887935c40e2eb7753a65ff45&pid=1-s2.0-S2666273624001591-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141391214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
JTCVS open
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1